A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)

Phase 3 Terminated 360 enrolled Pfizer

RandomizedParallel-groupQuadruple-blindTreatment

This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages 18 to 65, with generalized anxiety disorder.

Evaluation	Drug	Modality	Dose	Route
Subject	IMAGABALIN	Other / unclassified	225 mg	Oral
Subject	IMAGABALIN	Other / unclassified	300 mg	Oral
Comparator	Paroxetine	Small molecule	20 mg	Oral